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Although the adverse health effects of nanoparticles have been proposed and are being 
clarified, their aggravating effects on pre-existing pathological conditions have not been 
fully investigated. In this review, we provide insights into the immunotoxicity of both 
airborne and engineered nanoparticles as an exacerbating factor on hypersusceptible 
subjects, especially those with immune-mediated pulmonary inflammation, using our in 
vivo experimental model. First, we exhibit the effects of nanoparticles on pulmonary 
inflammation induced by bacterial endotoxin (lipopolysaccharide: LPS) as a disease 
model in innate immunity, and demonstrate that nanoparticles instilled through both an 
intratracheal tube and an inhalation system can exacerbate the lung inflammation. 
Second, we introduce the effects of nanoparticles on allergic pulmonary inflammation as 
a disease model in adaptive immunity, and show that repetitive pulmonary exposure to 
nanoparticles has aggravating effects on allergic inflammation, including adjuvant 
effects on Th2-milieu. Third, we show that very small nanoparticle exposure exacerbates 
emphysematous pulmonary inflammation, which is concomitant with enhanced lung 
expression of proinflammatory molecules (including those that are innate immunity 
related). Taken together, nanoparticle exposure may synergistically facilitate 
pathological pulmonary inflammation via both innate and adaptive immunological 
impairment.  




Epidemiological studies have demonstrated a correlation between exposure to air pollutant particles at the 
concentrations currently found in major metropolitan areas and mortality and morbidity[1]. The 
concentration of particulate matter (PM) with a mass median aerodynamic diameter (a density-dependent 
unit of measure used to describe the diameter of the particle) 2.5 μm (PM2.5) is more closely associated 
with both acute and chronic respiratory effects and subsequent mortality than larger particles of 10 μm 
(PM10)[2]. In addition, one intriguing aspect of the epidemiologic data is that health effects of PM2.5 are 
primarily seen in subjects with predisposing factors, including pneumonia, asthma, chronic obstructive 
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pulmonary disease, compromised immune systems, atherosclerosis, age over 65 years, and possible 
depressive state[3,4,5,6]. Partially consistent with the epidemiological studies, we and others have 
experimentally demonstrated that diesel exhaust particles (DEP), major contributors to environmental 
PM2.5 in urban areas, exhibit respiratory toxicity with or without predisposing pathologies, including 
allergic asthma, pulmonary emphysema, and acute renal failure (although we did not provide evidence 
that DEP significantly exacerbated a murine model of pulmonary emphysema in our system[7]) in 
vivo[8,9,10,11,12,13,14,15,16].  
To date, nanoparticles, particles <0.1 μm in mass median aerodynamic diameter, have been shown to 
be increasing in ambient air[17]. Recent measurements indicate that nanoparticle numbers in ambient air 








, with mass concentrations of >50 μg/m3 near major 
highways[18,19]. On the other hand, nanotechnology is now advancing at an incredible pace, such that it 
is has created an alternative industrial revolution over the past few years[20]. Consistent with this, the use 
of engineered nanoparticles (called as “nanomaterials”) has been rapidly increasing in commercial 
applications. As these particles/materials have become more widespread, many questions have arisen 
regarding the adverse effects they may have on the environment as alternative inhalable toxicants. In 
particular, due to their sizes, characteristics, and/or existing pattern, nanoparticles/nanomaterials have 
been implicated in cardiopulmonary system effects[21]. Furthermore, compared to larger particles, 
nanoparticles/nanomaterials have a higher deposition rate in the peripherial lung, they can cross the 
pulmonary epithelium and reach the interstitium[22], and may thus be systemically distributed in the 
bloodstream[23], raising the possibility to render larger degree of inflammation. Nanoparticle/ 
nanomaterials have an enhanced capacity to produce reactive oxygen species (ROS) and, consequently, 
have a widespread toxicity[24,25,26], as do other types of PM (with relatively larger particle size), since 
ROS generation by particles can exert protein, lipid, and membrane damage[27,28]. For example, 
transition metals and redox-cycling organic chemical components on the particle surface can also 
participate in ROS generation characterized by the formation of O2
-
 through dismutation or Fenton 
reaction[28]. Indeed, it has been reported that nanomaterial exposure itself induces lung inflammation as 
for carbon nanotube and titanium dioxide, gold, and quantum dot[29,30,31,32,33,34]. These 
particle/material exposures also reportedly influence/promote cardiopulmonary systems in the presence of 
predisposing diseases in human studies[35,36]. However, biological evidence concerning the promoting 
effects of nanoparticles on predisposing subjects has been less studied. Besides their toxic property on 
health, therefore, it should be experimentally ascertained whether they also aggravate pre-existing 
pathological conditions and their underlying mechanisms should be resolved. In this review, we will 
discuss the impact of nanoparticles as immunological enhancers in the respiratory system. 
EFFECTS OF NANOPARTICLES ON BACTERIAL ENDOTOXIN-ELICITED 
PULMONARY INFLAMMATION 
A glycolipid of Gram-negative bacteria, known as endotoxin or lipopolysaccharide (LPS), stimulates host 
cells via innate immunity[37]. In animal models, intratracheal administration of LPS causes lung cytokine 
expression, neutrophil recruitment, and lung injury[38]. LPS is found in the bronchoalveolar lavage 
(BAL) fluid of patients with pneumonia[39] and acute respiratory distress syndrome[40], which 
sometimes results in a fatal outcome. In addition, LPS is a significant constituent of many air pollutant 
particles and has accordingly been implicated in the adverse effects of PM[41]. In accordance with the 
close links among LPS, lung inflammation (injury), and PM, we have previously shown that intratracheal 
administration of DEP and their components facilitates lung inflammation induced by LPS[14,42].  
We previously examined the effects of pulmonary exposure to nanoparticles on lung inflammation 
related to LPS in mice. Vehicle, two different types (particle size: 14 and 56 nm) of carbon black 
nanoparticles (CBNP), LPS, or LPS + CBNP was administered intratracheally, and parameters of lung 
inflammation and coagulation were evaluated. CBNP alone induced slight lung inflammation and 
significant pulmonary edema as compared with the vehicle. The 14-nm CBNP intensively aggravated 
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LPS-elicited lung inflammation and pulmonary edema, which was concomitant with the enhanced lung 
expression of interleukin (IL)-1β, macrophage inflammatory protein (MIP)-1α, macrophage 
chemoattractant protein (MCP)-1, MIP-2, and keratinocyte chemoattractant (KC) in overall trend, 
whereas the 56-nm CBNP did not show apparent effects. Immunoreactivity for 8-hydroxyguanosine 
(OHdG), a proper marker for oxidative stress, was more intense in the lung from the LPS + 14-nm CBNP 
group than in that from the LPS group. Taken together, CBNP can aggravate lung inflammation related to 
bacterial endotoxin, which is more prominent with smaller particles. The enhancing effect may be 
mediated, at least partly, via the increased local expression of proinflammatory cytokines and via the 
oxidative stress[43]. 
Furthermore, we examined the adverse effects of engineered nanoparticles on this pathological 
model. In brief, Institute for Cancer Research (ICR) male mice were divided into eight experimental 
groups that intratracheally received vehicle, three sizes (15, 50, or 100 nm) of TiO2 nanoparticles, LPS, or 
LPS + TiO2 nanoparticles. Twenty-four hours after the treatment, this type of nanoparticle exacerbated 
the lung inflammation and edema elicited by LPS, with an overall trend of amplified lung expressions of 
cytokines, such as IL-1β, MCP-1, and KC. LPS + nanoparticles, especially with size <50 nm, elevated 
circulatory levels of IL-1β, MCP-1, and KC as compared with LPS alone. The enhancement tended 
overall to be greater with the smaller nanoparticles than with the larger ones. These results suggest that 
engineered nanoparticles also exacerbate lung inflammation related to LPS and accompanying systemic 
inflammation, and the exacerbation is more prominent with smaller nanoparticles than with larger 
particles[44]. Additionally, we demonstrated that latex nanoparticles[45] and carbon nanotubes[46] have 
similar aggravating potential on the lung pathophysiology. 
Our next study was conducted to determine whether inhaled exposure to diesel engine–derived 
nanoparticles also exacerbates the model. ICR mice were exposed for 5 h to clean air or diesel engine–
derived nanoparticles at a concentration of 15, 36, or 169 μg/m3 after intratracheal challenge with LPS or 
vehicle, and were sacrificed for evaluation 24 h after the intratracheal challenge. Exposure to nanoparticles 
alone did not elicit lung inflammation. Nanoparticle inhalation exaggerated LPS-elicited inflammatory cell 
recruitment in the BAL fluid and lung parenchyma as compared with clean air inhalation in a concentration-
dependent manner. Lung homogenates derived from the LPS + nanoparticle groups tended to have an 
increased tumor necrosis factor-α level and chemotaxis activity for polymorphonuclear leukocytes as 
compared to those from the LPS group or the corresponding nanoparticle groups. Nanoparticle inhalation 
did not significantly increase the lung expression of proinflammatory cytokines or influence systemic 
inflammation. Isolated alveolar macrophages from nanoparticle-exposed mice showed a greater production 
of IL-1β and KC stimulated with ex vivo LPS challenge than those from clean air–exposed mice, although 
the differences did not reach significance. These results suggest that acute exposure to diesel nanoparticles 
exacerbates lung inflammation induced by LPS[47]. In sum, nanoparticle exposure exacerbates acute lung 
inflammation related to bacterial endotoxin (Fig. 1).  
EFFECTS OF NANOPARTICLES ON ALLERGEN-ELICITED PULMONARY 
INFLAMMATION 
Bronchial asthma has been recognized as chronic airway inflammation with hyper-responsiveness that is 
characterized by an increase in the number of activated lymphocytes and eosinophils[48]. A number of 
studies have shown that various particles, including carbon black, can enhance allergic 
sensitization[49,50,51], which is referred to as “adjuvant effect”. As well, carbon black has been 
demonstrated to enhance the proliferation of antibody-forming cells and both IgE and IgG levels[52,53]. 
Ultrafine particles (PM and carbon black) reportedly exaggerate allergic airway inflammation in 
vivo[54,55]. However, all studies have failed to pay attention to the size of the particles. Therefore, no 
research has addressed the size effects of particles or nanoparticles on airway biology in the presence or 
absence of allergen in vivo. Given the hypothesis, we investigated the effects of CBNP with a diameter of  
14 or 56 nm on allergen-related airway inflammation. ICR mice were divided into six experimental groups. 




FIGURE 1. Proposal schema for aggravating effects of nanoparticles/nanomaterials on immune-mediated 
pulmonary inflammation. Regarding the impact on innate immunity, these particles may directly/indirectly 
influence on related cell populations, such as macrophages/monocytes, neutrophils, dendritic cells, natural killer 
cells, etc. As for adaptive immunity, in turn, nanoparticles/nanomaterials may potentially activate dendritic 
cells, lymphocytes, eosinophils, and mast cells/basophils. Furthermore, cell-cell interaction, intracellular 
signaling pathways, and/or chemical mediators, such as proinflammatory cytokines, complement system, and 
lipid mediators, may also be targets for these particles.  
Vehicle, two sizes of CBNP, ovalbumin (OVA), and OVA + CBNP were administered intratracheally. 
The cellular profile of BAL fluid; lung histology; expression of cytokines, chemokines, and 8-OHdG; and 
immunoglobulin production were studied. CBNP with a diameter of 14 or 56 nm aggravated allergen-
related airway inflammation characterized by the infiltration of eosinophils, neutrophils, and mononuclear 
cells, and by an increase in the number of goblet cells in the bronchial epithelium. CBNP with allergen 
increased protein levels of IL-5, IL-6, IL-13, eotaxin, MCP-1, and RANTES (regulated on activation and 
normal T cells expressed and secreted) in the lung as compared with allergen alone. The formation of 8-
OHdG was moderately induced by CBNP or allergen alone, and was markedly enhanced by allergen plus 
CBNP as compared with CBNP or allergen alone. The aggravation was more prominent with 14-nm 
CBNP than with 56-nm CBNP in terms of the overall trend. CBNP with a diameter of 14 nm exhibited 
adjuvant activity for total IgE and antigen-specific IgG and IgE. CBNP can aggravate allergen-related 
airway inflammation and immunoglobulin production, which becomes more prominent with smaller 
particles. The enhancement may be mediated, at least partly, by the increased local expression of IL-5 and 
eotaxin, and also by the modulated expression of IL-13, RANTES, MCP-1, and IL-6[56]. Consistent with 
our study, de Haar and colleagues have previously shown that nanoparticles (14 and 29 nm) potently 
facilitate allergic airway inflammation as compared to fine particles (250 and 260 nm)[57].  
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In ongoing reports, CBNP alone or OVA alone moderately enhanced cholinergic airway reactivity, as 
assessed by total respiratory system resistance (R) and Newtonian resistance (Rn). All the parameters of 
lung responsiveness, such as R, compliance, elastance, Rn, tissue damping, and tissue elastance, were 
worse in the OVA + CBNP groups than in the vehicle group, the corresponding CBNP groups, or the 
OVA group. The lung mRNA level for mucin (Muc)5ac was significantly higher in the OVA group than 
in the vehicle group, and further increased in the OVA + CBNP groups than in the OVA or CBNP groups. 
These data suggest that CBNP can facilitate lung physiology, such as airway hyper-responsiveness, 
especially in the presence of allergen. Further, the effects may be mediated, at least partly, through the 
enhanced lung expression of Muc5ac[58].  
We recently demonstrated that (single- and multiwalled) carbon nanotubes promote allergic airway 
inflammation in mice, which may be partly through enhanced oxidative stress in the airway and the 
inappropriate activation of antigen-presenting cells, including dendritic cells (in vitro)[59,60]. In addition, 
other groups have reported the similar impacts of nanoparticles (carbon nanotubes, TiO2, gold) as we did 
on animal allergic asthma models[57,61,62,63]. Moreover, as for cellular contribution, we and others 
have claimed that antigen-presenting cells, such as dendritic cells, are important target cell populations for 
the adjuvant activity of nanoparticles[64,65,66]. Taken together, nanoparticle exposure can exacerbate 
allergic asthma (Fig. 1).   
EFFECTS OF NANOPARTICLES ON ELASTASE-ELICITED PULMONARY 
INFLAMMATION 
Chronic obstructive pulmonary disease (COPD) is one of the chronic inflammatory diseases of the lung 
that is associated with reduced maximal expiratory flow, increased lung volume, and alveolar wall 
destruction[67]. COPD is currently the fourth leading cause of death in the U.S., with up to 7 million 
patients diagnosed each year[68]. PM is epidemiologically implicated to link to the degree of symptoms 
of COPD[69,70,71]; however, biological evidence remains unclarified. We recently investigated the 
impact of pulmonary exposure to CBNP on COPD-like emphysematous lung injury induced by porcine 
pancreatic elastase (PPE) in mice. Vehicle, two sizes (14 and 56 nm) of CBNP, PPE, or PPE + CBNP was 
administered intratracheally; thereafter, parameters of inflammatory lung changes were evaluated at 
several time points. CBNP of 14 nm significantly induced acute lung inflammation in nonelicited 
subjects, and aggravated PPE-elicited airway inflammation with infiltrated neutrophils and eosinophils at 
an early stage, which was concomitant with the enhanced lung expression of proinflammatory cytokines 
related to innate immunity, such as IL-1β, and chemokines, such as KC. Further, 14-nm CBNP 
exaggerated emphysematous lung structural changes at a delayed stage. On the other hand, 56-nm CBNP 
induced lung inflammation, but did not influence PPE-elicited pathophysiologic traits in the lung. Taken 
together, CBNP at an optimal size and dose can exacerbate PPE-induced pulmonary inflammatory 
response and emphysema. This enhancement may be mediated, at least partly, via the increased local 
expression of proinflammatory molecules([72], and unpublished data) (Fig. 1).  
SUMMARY 
In summary, both airborne and engineered nanoparticles/nanomaterials can facilitate pathological 
pulmonary inflammation, sometimes with synergism, implying that particle size plays a critical role in 
determining the extent of these types of immune-mediated pulmonary inflammation. Regarding the 
impact on innate immunity, these particles may directly/indirectly influence on related cell populations, 
such as macrophages/monocytes, neutrophils, dendritic cells, natural killer cells, etc. As for adaptive 
immunity, in turn, nanoparticles/nanomaterials may potentially activate dendritic cells, lymphocytes, 
eosinophils, and mast cells/basophils. Furthermore, cell-cell interaction, intracellular signaling pathways, 
and/or chemical mediators, such as proinflammatory cytokines, complement system, and lipid mediators, 
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may also be targets for these particles (Fig. 1). Although it is easy to imagine that characteristics of the 
particles, such as physicochemical properties, electronic charge, aggregation rate, surface coating, 
colloidal stability, etc., are important for differences in the impact on immune modulation, future 
investigation warrants the matter. In any case, these previous findings indicate that nanoparticles/ 
nanomaterials potentiate an inflammatory response in subjects with lung inflammation, which might play 
a vital role in the pulmonary effects of airborne pollutants on the sensitive populations who have 
preceding respiratory immune-mediated diseases.  
ACKNOWLEDGMENT 
Special thanks to Prof. Takamichi Ichinose, Prof. Seishiro Hirano, Dr. Rie Yanagisawa, and Dr. Eiko 
Koike for greatly contributing to the work in the manuscript. The authors are supported by NIES grants 
and partly by Grants-in-Aid for Scientific Research (B) 18390188 (to K. Inoue) from the Japan Society 
for the Promotion of Science.   
REFERENCES 
1. Samet, J.M., Dominici, F., Curriero, F.C., Coursac, I., and Zeger, S.L. (2000) Fine particulate air pollution and 
mortality in 20 U.S. cities, 1987-1994. N. Engl. J. Med. 343, 1742–1749.  
2. Peters, A., Wichmann, H.E., Tuch, T., Heinrich, J., and Heyder, J. (1997) Respiratory effects are associated with the 
number of ultrafine particles. Am. J. Respir. Crit. Care Med. 155, 1376–1383. 
3. Szyszkowicz, M. (2007) Air pollution and emergency department visits for depression in Edmonton, Canada. Int. J. 
Occup. Med. Environ. Health 20, 241–245. 
4. Kunzli, N., Bridevaux, P.O., Liu, L.J., Garcia-Esteban, R., Schindler, C., Gerbase, M.W., Sunyer, J., Keidel, D., and 
Rochat, T. (2009) Traffic-related air pollution correlates with adult-onset asthma among never-smokers. Thorax 64, 
664–670. 
5. Neupane, B., Jerrett, M., Burnett, R.T., Marrie, T., Arain, A., and Loeb, M. (2010) Long-term exposure to ambient air 
pollution and risk of hospitalization with community-acquired pneumonia in older adults. Am. J. Respir. Crit. Care 
Med. 181, 47–53. 
6. Dockery, D.W., Pope, C.A., 3rd, Xu, X., Spengler, J.D., Ware, J.H., Fay, M.E., Ferris, B.G., Jr., and Speizer, F.E. 
(1993) An association between air pollution and mortality in six U.S. cities. N. Engl. J. Med. 329, 1753–1759. 
7. Inoue, K., Koike, E., and Takano, H. (2010) Comprehensive analysis of elastase-induced pulmonary emphysema in 
mice: effects of ambient existing particulate matters. Int. Immunopharmacol. 10, 1380–1389. 
8. Nemmar, A., Al-Salam, S., Zia, S., Yasin, J., Al Husseni, I., and Ali, B.H. (2010) Diesel exhaust particles in the lung 
aggravate experimental acute renal failure. Toxicol. Sci. 113, 267–277. 
9. Lopes, F.D., Pinto, T.S., Arantes-Costa, F.M., Moriya, H.T., Biselli, P.J., Ferraz, L.F., Lichtenfels, A.J., Saldiva, P.H., 
Mauad, T., and Martins, M.A. (2009) Exposure to ambient levels of particles emitted by traffic worsens emphysema 
in mice. Environ. Res. 109, 544–551. 
10. Inoue, K., Takano, H., Yanagisawa, R., Ichinose, T., Shimada, A., and Yoshikawa, T. (2005) Pulmonary exposure to 
diesel exhaust particles induces airway inflammation and cytokine expression in NC/Nga mice. Arch. Toxicol. 79, 
595–599.  
11. Ichinose, T., Furuyama, A., and Sagai, M. (1995) Biological effects of diesel exhaust particles (DEP). II. Acute 
toxicity of DEP introduced into lung by intratracheal instillation. Toxicology 99, 153–167. 
12. Ichinose, T., Yajima, Y., Nagashima, M., Takenoshita, S., Nagamachi, Y., and Sagai, M. (1997) Lung carcinogenesis 
and formation of 8-hydroxy-deoxyguanosine in mice by diesel exhaust particles. Carcinogenesis 18, 185–192. 
13. Takano, H., Yoshikawa, T., Ichinose, T., Miyabara, Y., Imaoka, K., and Sagai, M. (1997) Diesel exhaust particles 
enhance antigen-induced airway inflammation and local cytokine expression in mice. Am. J. Respir. Crit. Care Med. 
156, 36–42. 
14. Takano, H., Yanagisawa, R., Ichinose, T., Sadakane, K., Yoshino, S., Yoshikawa, T., and Morita, M. (2002) Diesel 
exhaust particles enhance lung injury related to bacterial endotoxin through expression of proinflammatory cytokines, 
chemokines, and intercellular adhesion molecule-1. Am. J. Respir. Crit. Care Med. 165, 1329–1335. 
15. Inoue, K., Takano, H., Sakurai, M., Oda, T., Tamura, H., Yanagisawa, R., Shimada, A., and Yoshikawa T. (2006) 
Pulmonary exposure to diesel exhaust particles enhances coagulatory disturbance with endothelial damage and 
systemic inflammation related to lung inflammation. Exp. Biol. Med. (Maywood) 231, 1626–1632. 
Inoue and Takano: Nanoparticles and Pulmonary Inflammation TheScientificWorldJOURNAL (2011) 11, 382–390 
 
 388 
16. Inoue, K., Koike, E., Takano, H., Yanagisawa, R., Ichinose, T., and Yoshikawa, T. (2009) Effects of diesel exhaust 
particles on antigen-presenting cells and antigen-specific Th immunity in mice. Exp. Biol. Med. (Maywood) 234, 200–
209. 
17. Cyrys, J., Stolzel, M., Heinrich, J., Kreyling, W.G., Menzel, N., Wittmaack, K., Tuch, T., and Wichmann, H.E. (2003) 
Elemental composition and sources of fine and ultrafine ambient particles in Erfurt, Germany. Sci. Total Environ. 
305, 143–156.  
18. Timonen, K.L., Hoek, G., Heinrich, J., Bernard, A., Brunekreef, B., de Hartog, J., Hameri, K., Ibald-Mulli, A., 
Mirme, A., Peters, A., Tiittanen, P., Kreyling, W.G., and Pekkanen, J. (2004) Daily variation in fine and ultrafine 
particulate air pollution and urinary concentrations of lung Clara cell protein CC16. Occup. Environ. Med. 61, 908–
914.  
19. Zhu, Y., Hinds, W.C., Kim, S., and Sioutas, C. (2002) Concentration and size distribution of ultrafine particles near a 
major highway. J. Air Waste Manag. Assoc. 52, 1032–1042.  
20. Service, R.F. (2004) Nanotoxicology. Nanotechnology grows up. Science 304, 1732–1734. 
21. Utell, M.J. and Frampton, M.W. (2000) Acute health effects of ambient air pollution: the ultrafine particle hypothesis. 
J. Aerosol Med. 13, 355–359. 
22. Oberdorster, G. (2001) Pulmonary effects of inhaled ultrafine particles. Int. Arch. Occup. Environ. Health 74, 1–8.  
23. Seaton, A., MacNee, W., Donaldson, K., and Godden, D. (1995) Particulate air pollution and acute health effects. 
Lancet 345, 176–178. 
24. Brown, D.M., Wilson, M.R., MacNee, W., Stone, V., and Donaldson, K. (2001) Size-dependent proinflammatory 
effects of ultrafine polystyrene particles: a role for surface area and oxidative stress in the enhanced activity of 
ultrafines. Toxicol. Appl. Pharmacol. 175, 191–199.  
25. Dick, C.A., Brown, D.M., Donaldson, K., and Stone, V. (2003) The role of free radicals in the toxic and inflammatory 
effects of four different ultrafine particle types. Inhal. Toxicol. 15, 39–52.  
26. Li, N., Sioutas, C., Cho, A., Schmitz, D., Misra, C., Sempf, J., Wang, M., Oberley, T., Froines, J., and Nel, A. (2003) 
Ultrafine particulate pollutants induce oxidative stress and mitochondrial damage. Environ. Health Perspect. 111, 
455–460.  
27. Nel, A., Xia, T., Madler, L., and Li, N. (2006) Toxic potential of materials at the nanolevel. Science 311, 622–627. 
28. Li, N., Xia, T., and Nel, A. (2008) The role of oxidative stress in ambient particulate matter-induced lung diseases and 
its implications in the toxicity of engineered nanoparticles. Free Radic. Biol. Med. 44, 1689–1699. 
29. Warheit, D.B., Laurence, B.R., Reed, K.L., Roach, D.H., Reynolds, G.A., and Webb, T.R. (2004) Comparative 
pulmonary toxicity assessment of single-wall carbon nanotubes in rats. Toxicol. Sci. 77, 117–125. 
30. Shvedova, A.A., Kisin, E.R., Mercer, R., Johnson, V.J., Potapovich, A.I., Tyurina, Y.Y., Gorelik, O., Arepalli, S., 
Schwegler-Berry, D., Hubbs, A.F., Antonini, J., Evans, D.E., Ku, B.K., Ramsey, D., Maynard, A., Kagan, V.E., 
Castranova, V., and Baron, P. (2005) Unusual inflammatory and fibrogenic pulmonary responses to single-walled 
carbon nanotubes in mice. Am. J. Physiol. Lung Cell. Mol. Physiol. 289, L698–708. 
31. Chen, H.W., Su, S.F., Chien, C.T., Lin, W.H., Yu, S.L., Chou, C.C., Chen, J.J., and Yang, P.C. (2006) Titanium 
dioxide nanoparticles induce emphysema-like lung injury in mice. FASEB J. 20, 2393–2395. 
32. Warheit, D.B., Webb, T.R., Sayes, C.M., Colvin, V.L., and Reed, K.L. (2006) Pulmonary instillation studies with 
nanoscale TiO2 rods and dots in rats: toxicity is not dependent upon particle size and surface area. Toxicol. Sci. 91, 
227–236. 
33. Gosens, I., Post, J.A., de la Fonteyne, L.J., Jansen, E.H., Geus, J.W., Cassee, F.R., and de Jong, W.H. (2010) Impact 
of agglomeration state of nano- and submicron sized gold particles on pulmonary inflammation. Part. Fibre. Toxicol. 
7, 37.  
34. Jacobsen, N.R., Moller, P., Jensen, K.A., Vogel, U., Ladefoged, O., Loft, S., and Wallin, H. (2009) Lung 
inflammation and genotoxicity following pulmonary exposure to nanoparticles in ApoE-/- mice. Part. Fibre. Toxicol. 
6, 2. 
35. Gong, H., Jr., Linn, W.S., Clark, K.W., Anderson, K.R., Sioutas, C., Alexis, N.E., Cascio, W.E., and Devlin, R.B. 
(2008) Exposures of healthy and asthmatic volunteers to concentrated ambient ultrafine particles in Los Angeles. 
Inhal. Toxicol. 20, 533–545. 
36. Frampton, M.W., Stewart, J.C., Oberdorster, G., Morrow, P.E., Chalupa, D., Pietropaoli, A.P., Frasier, L.M., Speers, 
D.M., Cox, C., Huang, L.S., and Utell, M.J. (2006) Inhalation of ultrafine particles alters blood leukocyte expression 
of adhesion molecules in humans. Environ. Health Perspect. 114, 51–58. 
37. Vincenti, M.P., Burrell, T.A., and Taffet, S.M. (1992) Regulation of NF-kappa B activity in murine macrophages: 
effect of bacterial lipopolysaccharide and phorbol ester. J. Cell. Physiol. 150, 204–213.  
38. Ulich, T.R., Watson, L.R., Yin, S.M., Guo, K.Z., Wang, P., Thang, H., and del Castillo, J. (1991) The intratracheal 
administration of endotoxin and cytokines. I. Characterization of LPS-induced IL-1 and TNF mRNA expression and 
the LPS-, IL-1-, and TNF-induced inflammatory infiltrate. Am. J. Pathol. 138, 1485–1496.  
39. Flanagan, P.G., Jackson, S.K., and Findlay, G. (2001) Diagnosis of gram negative, ventilator associated pneumonia 
by assaying endotoxin in bronchial lavage fluid. J. Clin. Pathol. 54, 107–110. 
Inoue and Takano: Nanoparticles and Pulmonary Inflammation TheScientificWorldJOURNAL (2011) 11, 382–390 
 
 389 
40. Martin, T.R., Rubenfeld, G.D., Ruzinski, J.T., Goodman, R.B., Steinberg, K.P., Leturcq, D.J., Moriarty, A.M., Raghu, 
G., Baughman, R.P., and Hudson, L.D. (1997) Relationship between soluble CD14, lipopolysaccharide binding 
protein, and the alveolar inflammatory response in patients with acute respiratory distress syndrome. Am. J. Respir. 
Crit. Care Med. 155, 937–944. 
41. Becker, S., Fenton, M.J., and Soukup, J.M. (2002) Involvement of microbial components and toll-like receptors 2 and 
4 in cytokine responses to air pollution particles. Am. J. Respir. Cell Mol. Biol. 27, 611–618. 
42. Yanagisawa, R., Takano, H., Inoue, K., Ichinose, T., Sadakane, K., Yoshino, S., Yamaki, K., Kumagai, Y., 
Uchiyama, K., Yoshikawa, T., and Morita, M. (2003) Enhancement of acute lung injury related to bacterial endotoxin 
by components of diesel exhaust particles. Thorax 58, 605–612. 
43. Inoue, K., Takano, H., Yanagisawa, R., Hirano, S., Sakurai, M., Shimada, A., and Yoshikawa, T. (2006) Effects of 
airway exposure to nanoparticles on lung inflammation induced by bacterial endotoxin in mice. Environ. Health 
Perspect. 114, 1325–1330. 
44. Inoue, K., Takano, H., Ohnuki, M., Yanagisawa, R., Sakurai, M., Shimada, A., Mizushima, K., and Yoshikawa, T. 
(2008) Size effects of nanomaterials on lung inflammation and coagulatory disturbance. Int. J. Immunopathol. 
Pharmacol. 21, 197–206. 
45. Inoue, K., Takano, H., Yanagisawa, R., Koike, E., and Shimada, A. (2009) Size effects of latex nanomaterials on lung 
inflammation in mice. Toxicol. Appl. Pharmacol. 234, 68–76. 
46. Inoue, K., Takano, H., Koike, E., Yanagisawa, R., Sakurai, M., Tasaka, S., Ishizaka, A., and Shimada, A. (2008) 
Effects of pulmonary exposure to carbon nanotubes on lung and systemic inflammation with coagulatory disturbance 
induced by lipopolysaccharide in mice. Exp. Biol. Med. (Maywood) 233, 1583–1590. 
47. Inoue, K.I., Takano, H., Yanagisawa, R., Hirano, S., Kobayashi, T., Fujitani, Y., Shimada, A., and Yoshikawa, T. 
(2007) Effects of inhaled nanoparticles on acute lung injury induced by lipopolysaccharide in mice. Toxicology 238, 
99–110. 
48. Agrawal, D.K. and Shao, Z. (2010) Pathogenesis of allergic airway inflammation. Curr. Allergy Asthma Rep. 10, 39–
48. 
49. Maejima, K., Tamura, K., Taniguchi, Y., Nagase, S., and Tanaka H. (1997) Comparison of the effects of various fine 
particles on IgE antibody production in mice inhaling Japanese cedar pollen allergens. J. Toxicol. Environ. Health 52, 
231–248. 
50. Lambert, A.L., Dong, W., Winsett, D.W., Selgrade, M.K., and Gilmour, M.I. (1999) Residual oil fly ash exposure 
enhances allergic sensitization to house dust mite. Toxicol. Appl. Pharmacol. 158, 269–277. 
51. Lambert, A.L., Dong, W., Selgrade, M.K., and Gilmour, M.I. (2000) Enhanced allergic sensitization by residual oil 
fly ash particles is mediated by soluble metal constituents. Toxicol. Appl. Pharmacol. 165, 84–93. 
52. Lovik, M., Hogseth, A.K., Gaarder, P.I., Hagemann, R., and Eide, I. (1997) Diesel exhaust particles and carbon black 
have adjuvant activity on the local lymph node response and systemic IgE production to ovalbumin. Toxicology 121, 
165–178. 
53. van Zijverden, M., van der Pijl, A., Bol, M., van Pinxteren, F.A., de Haar, C., Penninks, A.H., van Loveren, H., and 
Pieters, R. (2000) Diesel exhaust, carbon black, and silica particles display distinct Th1/Th2 modulating activity. 
Toxicol. Appl. Pharmacol. 168, 131–139. 
54. Last, J.A., Ward, R., Temple, L., Pinkerton, K.E., and Kenyon, N.J. (2004) Ovalbumin-induced airway inflammation 
and fibrosis in mice also exposed to ultrafine particles. Inhal. Toxicol. 16, 93–102. 
55. Al-Humadi, N.H., Siegel, P.D., Lewis, D.M., Barger, M.W., Ma, J.Y., Weissman, D.N., and Ma, J.K. (2002) The 
effect of diesel exhaust particles (DEP) and carbon black (CB) on thiol changes in pulmonary ovalbumin allergic 
sensitized Brown Norway rats. Exp. Lung Res. 28, 333–349. 
56. Inoue, K., Takano, H., Yanagisawa, R., Sakurai, M., Ichinose, T., Sadakane, K., and Yoshikawa, T. (2005) Effects of 
nano particles on antigen-related airway inflammation in mice. Respir. Res. 6, 106. 
57. de Haar, C., Hassing, I., Bol, M., Bleumink, R., and Pieters, R. (2006) Ultrafine but not fine particulate matter causes 
airway inflammation and allergic airway sensitization to co-administered antigen in mice. Clin. Exp. Allergy 36, 
1469–1479. 
58. Inoue, K., Takano, H., Yanagisawa, R., Sakurai, M., Abe, S., Yoshino, S., Yamaki, K., and Yoshikawa, T. (2007) 
Effects of nanoparticles on lung physiology in the presence or absence of antigen. Int. J. Immunopathol. Pharmacol. 
20, 737–744. 
59. Inoue, K., Koike, E., Yanagisawa, R., Hirano, S., Nishikawa, M., and Takano, H. (2009) Effects of multi-walled 
carbon nanotubes on a murine allergic airway inflammation model. Toxicol. Appl. Pharmacol. 237, 306–316. 
60. Inoue, K., Yanagisawa, R., Koike, E., Nishikawa, M., and Takano, H. (2010) Repeated pulmonary exposure to single-
walled carbon nanotubes exacerbates allergic inflammation of the airway: possible role of oxidative stress. Free 
Radic. Biol. Med. 48, 924–934. 
61. Nygaard, U.C., Hansen, J.S., Samuelsen, M., Alberg, T., Marioara, C.D., and Lovik, M. (2009) Single-walled and 
multi-walled carbon nanotubes promote allergic immune responses in mice. Toxicol. Sci. 109, 113–123. 
62. Ryman-Rasmussen, J.P., Tewksbury, E.W., Moss, O.R., Cesta, M.F., Wong, B.A., and Bonner, J.C. (2009) Inhaled 
multiwalled carbon nanotubes potentiate airway fibrosis in murine allergic asthma. Am. J. Respir. Cell Mol. Biol. 40, 
349–358. 
Inoue and Takano: Nanoparticles and Pulmonary Inflammation TheScientificWorldJOURNAL (2011) 11, 382–390 
 
 390 
63. Hussain, S., Vanoirbeek, J.A., Luyts, K., De Vooght, V., Verbeken, E., Thomassen, L.C., Martens, J.A., Dinsdale, D., 
Boland, S., Marano, F., Nemery, B., and Hoet, P.H. (2010) Lung exposure to nanoparticles modulates an asthmatic 
response in a mouse model of asthma. Eur. Respir. J. [Epub ahead of print] 
64. Koike, E., Takano, H., Inoue, K., Yanagisawa, R., and Kobayashi, T. (2008) Carbon black nanoparticles promote the 
maturation and function of mouse bone marrow-derived dendritic cells. Chemosphere 73, 371–376. 
65. Koike, E., Takano, H., Inoue, K., Yanagisawa, R., Sakurai, M., Aoyagi, H., Shinohara, R., and Kobayashi, T. (2008) 
Pulmonary exposure to carbon black nanoparticles increases the number of antigen-presenting cells in murine lung. 
Int. J. Immunopathol. Pharmacol. 21, 35–42. 
66. de Haar, C., Kool, M., Hassing, I., Bol, M., Lambrecht, B.N, and Pieters, R. (2008) Lung dendritic cells are 
stimulated by ultrafine particles and play a key role in particle adjuvant activity. J. Allergy Clin. Immunol. 121, 1246–
1254. 
67. Pauwels, R.A., Buist, A.S., Calverley, P.M., Jenkins, C.R., and Hurd, S.S. (2001) Global strategy for the diagnosis, 
management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic 
Obstructive Lung Disease (GOLD) Workshop summary. Am. J. Respir. Crit. Care Med. 163, 1256–1276. 
68. Croxton, T.L., Weinmann, G.G., Senior, R.M., and Hoidal, J.R. (2002) Future research directions in chronic 
obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 165, 838–844. 
69. Zanobetti, A., Bind, M.A., and Schwartz, J. (2008) Particulate air pollution and survival in a COPD cohort. Environ. 
Health 7, 48. 
70. Torres-Duque, C., Maldonado, D., Perez-Padilla, R., Ezzati, M., and Viegi, G. (2008) Biomass fuels and respiratory 
diseases: a review of the evidence. Proc. Am. Thorac. Soc. 5, 577–590. 
71. Euler, G.L., Abbey, D.E., Magie, A.R., and Hodgkin, J.E. (1987) Chronic obstructive pulmonary disease symptom 
effects of long-term cumulative exposure to ambient levels of total suspended particulates and sulfur dioxide in 
California Seventh-Day Adventist residents. Arch. Environ. Health 42, 213–222. 
72. Inoue, K., Yanagisawa, R., Koike, E., Ichinose, T., Tasaka, S., Kiyono, M., Nakamura, R., and Takano, H. Effects of 





This article should be cited as follows: 
Inoue, K.-I. and Takano, H. (2011) Aggravating impact of nanoparticles on immune-mediated pulmonary inflammation. 
TheScientificWorldJOURNAL 11, 382–390. DOI 10.1100/tsw.2011.44. 
 
 
